Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventional medications barely relieve. At UCSF, neuroscientist Jennifer Mitchell is testing a pharmaceutical form of LSD called MM120, which has shown striking results in reducing symptoms by promoting neuroplasticity and easing rigid thought patterns. In clinical trials, a single dose significantly outperformed standard treatments, offering hope to those who have found little relief elsewhere.
Source link
